For GSK’s Ramakrishnan, who has served as CDTO since 2021, the biggest challenge was helping her company get a head start in ...

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...

The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...

GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its ...

The US Food and Drug Administration (FDA) has approved GSK’s triazaacenaphthylene antibiotic, Blujepa (gepotidacin), for ...

GSK has developed a new propellant technology for inhaler devices that drastically reduces their use of greenhouse gases, which perhaps surprisingly account for nearly half (49%) of the group’s ...

GSK Plc is pushing the UK government to give pharmaceutical companies more access to its public health data troves, to ...

The study will analyse electronic health records of 65- and 66-year olds from the UK’s National Health Service (NHS).

In this article, we are going to take a look at where GSK plc (NYSE:GSK ... when compared to verticals such as industrials and technology, such that President Trump would intend to enlarge ...

The EMA has agreed to review GSK’s application to expand Nucala’s use as an add-on maintenance for individuals with COPD.

Hanon meanwhile is joined at Vicebio by two other ex-GSK staffers – Dr Giovanni Della Cioppa and Dr Jean Smal – who will serve as chief medical officer and chief technology officer ...

The Food and Drug Administration on Tuesday approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new approvals the British drugmaker ...